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Abstract
Background The cobalamin E (cblE) (MTRR, methionine
synthase reductase) and cobalamin G (cblG) (MTR, methio-
nine synthase) defects are rare inborn errors of cobalamin
metabolism leading to impairment of the remethylation of
homocysteine to methionine.
Methods Information on clinical and laboratory data at initial
full assessment and during the course of the disease, treatment,
outcome and quality of life was obtained in a survey-based,
retrospective study from physicians caring for patients with
the CblE or CblG defect. In addition, data on enzyme studies
in cultured skin fibroblasts and mutations in the MTRR and
MTR gene were analysed.
Results In 11 cblE and 13 cblG patients, failure to thrive,
feeding problems, delayed milestones, muscular hypotonia,
cognitive impairment and macrocytic anaemia were the most
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frequent symptoms. Delay in diagnosis depended on age at
first symptom and clinical pattern at presentation and corre-
lated significantly with impaired communication abilities at
follow-up. Eighteen/22 patients presented with brain atrophy
or white matter disease. Biochemical response to treatment
with variable combinations of betaine, cobalamin, folate was
significant. The overall course was considered improving (n=
8) or stable (n=15) in 96 % of patients, however the average
number of CNS symptoms per patient increased significantly
over time and 16 of 23 patients were classified as develop-
mentally delayed or severely handicapped. In vitro enzyme
analysis data showed no correlation with outcome.
Predominantly private mutations were detected and no geno-
type– phenotype correlations evident.
Conclusions The majority of patients with the cblE and cblG
defect show limited clinical response to treatment and have
neurocognitive impairment.
Introduction
The cobalamin E (cblE, OMIM 236270) and cobalamin G
(cblG, OMIM 250940) complementation groups are rare in-
born errors of intracellular cobalamin (cbl) metabolism. The
metabolic block results in impairment of remethylation of
homocysteine (Hcy) to methionine (Met) which is catalysed
by the cytosolic enzymemethionine synthase (MTR, gene locus
1q43, defective in the cblG defect) and its closely associated
enzyme methionine synthase reductase (MTRR, gene locus
5p15.31, defective in the cblE defect) that maintains MTR in
its functional reduced status. Both disorders follow an autoso-
mal recessive inheritance pattern (Watkins et al 2002).
Until now, a number of case reports and small case series
on a total of less than 50 patients with either the cblE or the
cblG defect have been published. In the majority of published
patients, initial symptoms developed in the first weeks of life
or in early childhood (Zavadakova et al 2005).
The clinical patterns of the cblE and the cblG defect seem
to be indistinguishable, except for a subgroup of patients
homozygous for the c.1361C > T mutation in theMTRR gene
without neurological involvement but exclusively macrocytic
anaemia (Vilaseca et al 2003), but this question has not been
formally addressed until now. In general, a pattern of haema-
tological, neurological and ophthalmological symptoms is
characteristic for the disorders. The most frequently reported
symptoms are megaloblastic/macrocytic anemia or macrocy-
tosis (Fowler et al 1997; Müller et al 2007; Richard et al 2013;
Schuh et al 1984; Steen et al 1997; Vilaseca et al 2003;
Zavadakova et al 2002, 2005; Carmel et al 1988; Harding
et al 1997; Labrune et al 1999; Outteryck et al 2012); devel-
opmental delay, cognitive dysfunction or mental retardation
(Fowler et al 1997; Müller et al 2007; Richard et al 2013;
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Rosenblatt et al 1985; Schuh et al 1984; Steen et al 1997;
Zavadakova et al 2002, 2005; Carmel et al 1988; Kvittingen
et al 1997; Outteryck et al 2012; Poloschek et al 2005);
seizures (Müller et al 2007; Richard et al 2013; Steen et al
1997; Zavadakova et al 2002; Harding et al 1997; Kvittingen
et al 1997); pathological eye movements including nystagmus
and impaired visual acuity (Steen et al 1997; Zavadakova et al
2002; Kvittingen et al 1997; Outteryck et al 2012; Poloschek
et al 2005) and failure to thrive and feeding difficulties (Müller
et al 2007; Zavadakova et al 2002; Labrune et al 1999).
Microangiopathy and haemolytic uremic syndrome (HUS)
which have often been described in other inborn errors of
cobalamin metabolism such as the cblC defect have only very
rarely been reported in the cblE or cblG defect (Labrune et al
1999; Palanca et al 2013). Other less frequently reported
symptoms are pulmonary hypertension (Labrune et al 1999);
leukopenia or pancytopenia (Palanca et al 2013; Schuh et al
1984); recurrent infections (Harding et al 1997); altered con-
sciousness or microcephaly (Fowler et al 1997); hydrocepha-
lus and/or white matter disease (Müller et al 2007; Palanca
et al 2013; Zavadakova et al 2005; Outteryck et al 2012).
Treatment reportedly encompasses folic or folinic acid, be-
taine and a variety of cobalamin preparations (hydroxo-, cyano-
or methylcobalamin). The biochemical parameters total Hcy
(tHcy) and Met mostly respond well to treatment. However,
evaluation of clinical treatment efficacy is complex due to the
highly variable medication in the context of individual profiles
of mutations, age at onset of symptoms, time to initiation of
treatment and clinical presentation. Some authors found no
response at all to treatment in their patients (Steen et al 1997;
Palanca et al 2013). In a series of nine European cblE patients,
the overall impact of treatment on neurodevelopmental disabil-
ities is considered “at most moderate” (Zavadakova et al 2005).
In other cases, treatment— especially when started early—was
beneficial (Müller et al 2007).
The aims of the present study are
i) to compare clinical signs and symptoms between pa-
tients with the cblE or the cblG defect
ii) to investigate factors related to delay in diagnosis
iii) to describe the clinical presentation at onset and during
the course of the disease in a larger series of patients
with the cblE / G defect
iv) to identify parameters (e.g. age at initial symptoms,
delay in diagnosis, treatment, biochemical/genetic pa-
rameters) correlating with outcome and quality of life
as rated by the referring physician
Methods
This retrospective study was approved by the local ethics
committee (Kantonale Ethikkommission Zürich; No. 2013-
0012). Recruitment of patients was based on fibroblast cell
lines which had been sent for diagnostic purposes to Basel/
Zürich, Switzerland and in which the CblE or CblG defect had
been proven by enzymatic studies including somatic and
complementation analysis.
Survey
All physicianswho had sent cell lines were asked to complete a
survey on clinical symptoms at onset and during the course of
the disease, outcome, burden of disease and treatment, bio-
chemical data and mutations. Informed consent was obtained
from patient(s) and/or the caregivers. The survey was devel-
oped on the basis of the literature on the cblE and cblG defect
and expert discussions. Questions addressed clinical symptoms
reported before as well as involvement of other organ systems,
e.g. metabolic crisis, failure to thrive, feeding problems,
vomiting, drowsiness or impaired consciousness, anaemia,
seizures, developmental delay, eye disease and hearing loss,
muscular hypotonia, movement disorder, impaired cognitive
and speech development, psychiatric and neurological symp-
toms, thromboembolic events, affection of the liver, kidney or
heart. Open questions asked for comments or invited to men-
tion any other signs or symptoms observed in the patient and
not addressed explicitly. In addition, physicians were asked to
give an overall estimation of the degree of the clinical course,
cognitive impairment, quality of life of the patient and his
parents, and behavioural and social issues on 5-point Likert
scales. (Survey provided as supplementary material.)
Cell cultures and in vitro enzyme studies
Data from diagnostic analyses, which had been performed
earlier in cultured skin fibroblasts from the study patients,
were included with informed consent from the patients/their
parents and referring clinicians. At time of diagnosis, synthe-
sis of methionine from [14C]formate had been determined in
intact fibroblasts as an indirect measure of methionine syn-
thase activity as described earlier (Suormala et al 2004). For
this assay cells were grown for 72 h in routine culture medium
(basal medium) without and with added hydroxocobalamin
(OH-Cbl, 1 mg/L medium) for evaluation of in vitro cobala-
min responsiveness. Synthesis of the cobalamin coenzymes,
methylcobalamin (MeCbl) the cofactor of methionine syn-
thase and adenosylcobalamin (AdoCbl) the cofactor of
methylmalonyl-CoA mutase, from [57Co]cyanocobalamin in
intact fibroblasts had been measured as described earlier
(Suormala et al 2004).
Mutation identification
For patients 3, 4, 5, 8, 10, 15, 16, 17, 19, 21 and 23, results of
externally performed molecular genetic studies were recorded.
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For the remaining patients, molecular genetic analyses were
performed in the Zürich laboratory as follows: Genomic DNA
and total RNAwere extracted from cultured patient fibroblasts
samples using the QIAamp DNA Mini Kit and RNeasy Kit
(Qiagen), respectively. To identify mutations, exons were am-
plified through PCR from genomicDNAusing flanking intronic
primers (primers available upon request) and subsequent se-
quencing by the ABI BigDye method (Life Technologies). In
cases where no or only one mutation was found, or to confirm
splicing defects, cDNAwas analysed following synthesis from
total RNA by RT-PCR using OneStep RT-PCR kit (Qiagen)
with direct sequencing of RT-PCR products.
Statistical analysis
Data were analysed using SPSS statistical software for
Macintosh, release 20 (SPSS Inc., Chicago, IL, USA).
Analyses were performed with two-sided tests with a p value
of<0.05 considered to be significant. Chi-squared analyses
were used to compare nominal variables across diagnostic
groups. Nonparametric Spearman–Brown rank correlations
were calculated in order to examine associations between
variables. McNemar tests were used to statistically compare
signs and symptoms at onset and during the course.
Results
Patient characteristics
Physicians caring for 47 patients were contacted and invited to
participate. In 21 cases, physicians did not respond or had no
information on where patients were followed. In two cases,
informed consent for participation was not available.
Ultimately, data sets were included in this retrospective survey
study from 11 patients (five males, six females) with the CblE
defect and 13 patients (eight males, five females) with the
CblG defect. Patients originated from Germany (n=6), Czech
Republic (n=5), Austria, the UK and Spain (each n=2),
Australia, Belgium, Greece, Italy, Slovakia, Slovenia, and
Turkey (each n=1). Parental consanguinity (2nd degree cous-
ins) was present in the Turkish patient only. Patient care was
predominantly in the hands of metabolic specialists (n=22)
and/or paediatric neurologists (n=21). The diagnosis of the
cblE or cblG defect was established on the basis of symptom-
oriented, selective metabolic screening in all patients and in no
case by newborn- or family screening.
Comparison of clinical presentation between patients
with the cblE or the cblG defect
Muscular hypotonia during the disease course was observed
more frequently in patients with the cblG defect (84 to 40 %;
p=0.039; Chi Square test). No other significant differences
were observed between cblE and cblG patients concerning
clinical presentation at onset or during the course of the
disease (Chi Square test, data not shown). Due to this almost
complete clinical overlap, all further analyses combined pa-
tients with both disorders.
Pregnancy and newborn period
Pregnancy complications were reported in two cases:
Intrauterine growth retardation in one and reduced fetal
movements in another patient. Mean gestational week at
birth was 39.5 weeks; three children were born preterm at
week 34, 36 and 37 respectively. Birth weight (mean
3234 g, range 1910–4100 g), length (mean 50.2 cm, range
45–55 cm) and head circumference (mean 34; range 31–
37 cm) were within the normal, age adjusted percentile
ranges. One patient presented with facial dysmorphic fea-
tures, ureteral duplication and external hydrocephalus at
birth.
Age at first clinical symptoms, time to treatment initiation
and diagnosis
Median age at first symptoms was 3 months (mean 2 years;
range 1 day to 20.7 years) (Fig. 1).
Median time from the first appearance of symptoms to
proven diagnosis (by enzymatic/molecular genetic studies)
was 1.4 years (range from 198 days to 11.7 years; mean
3.4 years). Since treatment was initiated as soon as the
disease was suspected from metabolic workup, time be-
tween first symptoms and treatment initiation was shorter
in all patients (median 3.3 months, mean 1.98 years, range
0 days to 10.8 years). Median age at treatment initiation
was 9 months (mean 4 years, range 1.5 months to
21.3 years). Age at disease onset correlated significantly
negative with feeding problems (p<0.01) and growth im-
pairment (p<0.05) indicating that these symptoms were
more frequent in early onset patients (Spearman rho,
Supplementary Table 1).
Delay in diagnosis
Delay in diagnosis was shorter in patients who developed
symptoms at an early age (p<0.05) and if feeding problems
(p<0.01), drowsiness/impaired consciousness (p<0.05) and
impaired growth (p<0.05) were present at disease onset
(Spearman rho, Supplementary Table 1).
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Clinical presentation at onset and during the course
of the disease (Fig. 2)
One patient with severe neurological symptoms and hyper-
tension had died at age 56 days. Mean age at follow-up was
11.9 years (range 12 months to 32 years, median 11.1 years).
Feeding problems, muscular hypotonia, cognitive impair-
ment and delayed development as well as macrocytic anaemia
were the most frequent symptoms. The comparison of the
frequency of single clinical symptoms both at onset and
during the course revealed no significant differences between
both measurement points for any of the signs or symptoms
(McNemar Test, data not shown). Clinical deterioration/crises
following infections or similar triggers was not observed and
the overall clinical course was considered improving in 33 %,
stable in 63 % and deteriorating in 4 % of cases by the
physicians. However, when combining parameters indicative
for central nervous system (CNS) involvement and visual
impairment (microcephaly, seizures, delayed achievement of
developmental milestones, cognitive impairment, impaired
speech, eye disease and psychiatric symptoms) to define a
score for “CNS/visual involvement”, the average number of
symptoms per patient was significantly lower at onset with
2.41 compared to 3.87 during the course (paired t-test; t=
−3.27, p=0.003) indicating a significant worsening over time.
Eye problems and visual impairment were mainly due to























n=1 at 6120 days
n=1 at 7560 days 
Fig. 1 Age at first symptoms
(cumulative frequency) in 24
patients with the cblE and cblG
defect
Fig. 2 Clinical presentation at
onset and during the course of the
disease (%) in 24 individuals with
the cblE and cblG defect
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retinopathy, nystagmus and strabismus; lens dislocation was
never observed.
CNS involvement was also evident in magnetic resonance
imaging studies, which were available for 22 patients.
Findings were normal in only four patients. Enlarged ventri-
cles or subarachnoidal spaces were described in 3/22, brain
atrophy in 10/22 and white matter changes in 8/22 patients. In
one patient, cerebellar atrophy and in another multiple mor-
phologic brain malformations (vermis hypoplasia, thin corpus
callosum and hydrocephalus) was present. Hydrocephalus
was encountered in four patients: one cblG patient had pre-
sented with facial dysmorphic features, ureteral duplication
and external hydrocephalus at birth, another with hydroceph-
alus and cerebral and optic nerve atrophy at age 2 months and
in two children internal hydrocephalus was observed at month
3 (cblE) and 7 (cblG), respectively. An overview of the main
clinical features observed in each individual patient is depicted
in Table 1.
Among the more rarely reported symptomswere sinus vein
thrombosis and deep vein thrombosis of the lower leg, occur-
ring each in a single patient. The deceased cblE patient had
developed ischemic–haemorrhagic basal ganglia lesions and
HUS during the course. A milder episode of HUS was record-
ed in a cblG patient at the age of two years. Liver disease was
reported in a single patient in terms of a non-specific discrete
elevation of bilirubin probably not related to the remethylation
defect but to a more frequent condition such as Gilbert-
Meulengracht syndrome. Skeletal abnormalities (e.g. osteo-
porosis, scoliosis) were mostly attributable to severe neuro-
logical disease.
Outcome and quality of life (QOL)
At the latest time of follow-up, two patients attended
Kindergarten; four a regular school, two a special school due
to impaired motor functions and 12 individuals required spe-
cial schooling due to impaired cognitive function. One subject
worked in a sheltered employment company. Twenty-one
individuals lived with their parents; one adult patient required
sheltered housing. Seventeen individuals were able to walk
without assistance and eating without assistance was possible
in 15 cases. In contrast, only seven subjects were able to
communicate without impairment, learning disabilities were
noticed in 15, behavioural problems in 11 and social problems
in nine patients. For assessment of QOL in patients and
caregivers, burden of treatment and impact of treatment on
biochemical and clinical parameters, as well as to obtain an
overall impression of the severity of handicap at the latest
follow-up, physicians were asked to give their overall estima-
tions on a 5-point Likert scale ranging from “strongly agree”
to “strongly disagree” (Supplementary Fig. 3). Fifty-seven
percent of physicians agreed or strongly agreed to the
statement “the patient is severely handicapped”; however, 64
and 74 % stated that their patients showed good biochemical
and clinical response to treatment. Patients’ and caregivers’
quality of life was estimated as “good” in 73 and 57 % of
responses respectively. Treatment was considered a “signifi-
cant burden” for the patient in 29 % of cases.
Additionally, relations between physicians’ overall ratings
of clinical and biochemical response, patients’ and caregivers’
QOL, burden of treatment for the patient and outcome and
age-related parameters as well as signs and symptoms at onset
and during the course of the disease were investigated.
Regarding outcome, early disease onset was significantly
associated with severe handicap, learning disabilities, social
problems, a higher frequency of neuro-ophthalmological
problems as well as lower proxy-rated patients’ and care-
givers’ QOL. In the long term, impaired ability to communi-
cate was seen more frequently in patients with longer delay to
diagnosis (p<0.05; Spearman rho; Supplementary Table 1).
Treatment
Biochemical response to treatment was evident in all patients.
Mean tHcy at diagnosis was 140 μmol/L (range: 53–279,
median 125.8 μmol/L) compared to 71 μmol/L (range 9–
141, median 77 μmol/L) under treatment. Met was low at
diagnosis (mean 10.9μmol/L; range: 0–28, median 9 μmol/L)
and increased under treatment (mean 32.9 μmol/L; range: 14–
85, median 27.5 μmol/L). Treatment was variable especially
concerning type of cobalamin preparations and the doses of
medications (Table 2).
Biochemical and molecular genetic characterization
and clinical parameters
Results of biochemical and molecular genetic characterization
are summarized in Supplementary Table 4. Allele frequencies
are summarized in Supplementary Table 5.
Enzymatic studies performed for diagnostic purposes
showed deficient methionine formation and cobalamin coen-
zyme synthesis consistent with the underlying defect in all
patients. Responsiveness of methionine synthesis to supple-
mentation of medium with OH-Cbl was observed in all cell
lines with a tendency towards higher levels in supplemented
medium for cblG compared with cblE lines. When comparing
individual clinical courses and outcome data with the results
of enzymatic studies in cultivated fibroblasts, no general/
obvious correlation between both data sets could be delineated.
Likewise, no relation between genotype and clinical pheno-
type was observed. Molecular genetic investigation revealed a
majority of private mutations without predominance for any
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single mutation or genotype. Eight novel mutations in MTRR
and 15 novel mutations in MTR were identified.
Discussion
In this retrospective survey on 24 individuals with the cblE or
cblG defect, signs and symptoms at onset and during the
course were recorded. No difference concerning the frequency
of clinical symptoms at any time was noted between cblE and
cblG patients except for muscular hypotonia during the
course, which is more frequently reported in patients with
the cblG defect. Due to this almost complete clinical overlap,
both disorders have been evaluated together.
Clinical features in the cohort are generally similar to those
published. The new information provided by the study is
generated by the investigation of symptoms both at onset
and during the course, MRI findings, outcome and everyday
abilities as well as QOL combined with enzymatic studies and
molecular genetic characterization of the patients.
Nevertheless, we are aware of the limitations of this retro-
spective survey study, which is with respect to the clinical
information which is based on proxy reports by physicians
and not on self-reported patient and caregiver’s observations.
Prenatal and birth-related problems are uncommon in the
cblE and cblG defects. Disease onset occurs in 92 % of
patients before the age of 3 years with a peak in the first year
of life where already 75 % of patients are symptomatic. The
characteristic clinical pattern encompasses feeding difficulties
and failure to thrive, macrocytic anaemia, neurocognitive
impairment and eye disease (nystagmus, abnormal eye move-
ments, impaired visual acuity, and strabismus). White matter
disease and brain atrophy are common features in the reported
cohort, thus supporting the hypothesis that reduced availabil-
ity of Met results in decreased S-adenosylmethionine avail-
ability and consecutively in an impairment of methylation
capacity, which has been related to hypomyelination in the
central nervous system (Surtees 1998).
Relatively rare manifestations in this cohort include hydro-
cephalus and HUS with four and three affected patients,
respectively. Renal failure following HUS occurred in the
deceased patient and in a milder form in another patient.
HUS associated with a fatal course of the disease has been
reported in another young child (Palanca et al 2013).
Metabolic crises are not a predominant feature of the disease
either at presentation or during the course and unscheduled
admissions became only necessary in less than one third of the
patients.
Two patients presented with the mild cblE phenotype with
only macrocytic anaemia in the absence of neurological symp-
toms. One was homozygous for the c.1361C>T mutation in
the MTRR gene as described before (Vilaseca et al 2003) but
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c.1678_1681del and c.1740C>G, thus indicating more than
one genotype being associated with this milder course of the
disease. Due to the large number of private mutations, no clear
genotype-phenotype correlation could be identified. Although
not a main aim of this study there appears to be no obvious
connection of the functional enzyme parameters we measured
in cultivated fibroblasts with clinical presentation, course or
outcome.
Like in other inborn errors of cobalamin metabolism, delay
in diagnosis and consequently time to initiation of adequate
treatment is significant. We investigated which parameters
correlate with a shorter interval between onset of symptoms
and diagnosis. A “typical metabolic” presentation with feed-
ing problems and altered consciousness in a very young child
prompts metabolic workup and leads to the correct diagnosis
more rapidly than the less uniform presentation in patients
with later onset disease. In the present cohort, delayed diag-
nosis correlates with the outcome parameter “reduced ability
to communicate” but not with other outcome parameters or
proxy-reported QOL.
Good response to early treatment in remethylation disor-
ders has been reported before (Müller et al 2007; Schiff et al
2011). However, in this study statistical analyses revealed no
difference between the observed frequency of symptoms at
onset and during the course of the disease. Beyond this,
analysis of the neuro-ophthalmological and psychiatric symp-
toms as combined in a single factor representing overall CNS
involvement revealed deterioration over time despite treat-
ment. These findings underline the severity of the diseases
which is also supported by the finding of a very high incidence
(18/22 patients) of pathological brain MRI findings as well as
cognitive, behavioural and social problems. One patient was
deceased and 57 % of the patients were considered “severely
handicapped”. However, physicians gave the overall
judgement that their patients mostly benefit from treatment
and considered the course of the disease to be improving or
stable in all survivors. We speculate that physicians might
have focused predominantly on the improving biochemical
parameters (tHcy, Met) and the non-CNS parameters such as
haematological problems and failure to thrive/feeding prob-
lems which remain stable or improve slightly. Additionally,
the progression of CNS abnormalities may in part simply
reflect the fact that some symptoms can only be attributed to
and assessed in older children (e.g. psychiatric and behaviour-
al issues).
Treatment strategies in cblE and cblG patients are very
variable in terms of different Cbl preparations and applications
as well as the large variation of doses for all medications.
Methionine was supplemented only in four patients; the ma-
jority of patients were treated with Cbl, folate or folinate and
betaine. THcy was lowered and Met increased in all treated
patients but the range of tHcy concentrations (maximum
141 μmol/L) suggests that optimal doses and forms of appli-
cation might not have been achieved in all cases. How to
determine the optimal dosage in the intracellular cobalamin
disorders is an unsolved issue at present. In patients with the
cblC defect, some authors argue in favour of general high-
dose OH-Cbl treatment (Carrillo-Carrasco et al 2009) while
others advise individual titration of the dose targeting optimal
biochemical response (Dionisi-Vici et al 2013). Since paren-
teral Cbl application is necessary in most cases, the number of
injections per week is an important issue for patients’ and
caregiver’s QOL (Dionisi-Vici et al 2013). It has not been
investigated systematically whether higher doses in general
are advantageous and if so, whether single high compared to
repeated lower doses changes clinical outcome in any of the
cobalamin defects effectively. Future studies addressing this
question in a standardized manner are needed. In general, it is
Table 2 Treatment in the cohort of 24 cblE and cblG patients
N Range mg/week Mean mg/week Median mg/week
OH-Cbl IM 10 0.25–20 7.9 6
OH-Cbl IV 2 2–7 4.5 –
OH-Cbl PO 3 1–7 5 7
















N Range mg/kg/d Mean mg/kg/d Median mg/kg/d
Betaine 22 51–282 161 185
N Range mg/d Mean mg/d Median mg/d
Folate 14 1.25–40 7.6 5
Folinate 9 1–45 13.5 7.5
Methionine 4 80–500 256 200
*In a non-responsive patient 1 mg OH-Cbl/week i.m. was changed to oral methyl-Cbl treatment
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difficult to evaluate the efficacy of treatment strategies in the
context of a disease highly variable in its clinical manifesta-
tions and genetic backgrounds. In addition, no standardized
follow-up strategies have been agreed on so far.
Factors determining proxy-rated QOL of life must be
interpreted cautiously. Due to the method used, our data might
predominantly depict physicians’ attitudes towards QOL.
Therefore, we limit the interpretation of the data to the obser-
vations that in general, physicians assigned good overall QOL
to patients and caregivers even though they considered their
patients significantly handicapped. Besides failure to thrive,
feeding problems and vomit ing , predominant ly
neurocognitive factors such as delayed achievement of mile-
stones, impaired speech and communication skills, seizures,
psychiatric problems and severe handicap correlate most sig-
nificantly with the perception of impaired QOL in patients and
caregivers.
In conclusion, this systematic study of the largest series of
patients so far, confirms that the cblE and cblG defects are
severe diseases with onset in the first years of life, poor
neurocognitive outcome and significant brain pathology.
There is wide overlap with the cblC defect, especially in
patients presenting with HUS, hydrocephalus or retinopathy.
In the cblC defect it has been hypothesized that the microan-
giopathy which underlies both HUS and pulmonary arterial
hypertension may be related to mutations at a specific site,
namely the c.276 nucleotide (Kömhoff 2013). In addition,
chronic communicating hydrocephalus may also be related
to vasculopathy in terms of reduced intracranial vessel com-
pliance that results in enhanced intracerebral pulse pressure
thus causing ventricle enlargement (Greitz 2007). However, in
the cblE and cblG defects no specific mutations/mutation sites
causing microangiopathy have yet been identified. Generally,
no genotype-phenotype or in vitro enzyme activity-phenotype
correlations can be derived in the cblE and cblG defects. The
exception seems to be homozygosity for the c.1361C>T
mutation in the MTRR gene, which may be more clearly
associated with an isolated macrocytic anaemia phenotype
than other genotypes (Vilaseca et al 2003). The clinical course
may be stabilized or slightly improved but not reversed by
treatment. Treatment strategies are variable and this study
points to the need to devise a consensus on preparations and
applications of cobalamin, drug dosages or standardized
follow-up strategies. Delay in diagnosis is significant, depends
on the age and clinical pattern at disease onset and correlates
with communicative abilities of the patient in the long-term.
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